Aurinia Pharmaceuticals Inc. (AUPH) Earnings History
Profitable28 years of earnings data (1998–2025) · Positive TTM net income
Loading earnings history...
Aurinia Pharmaceuticals Inc. (AUPH) Earnings Overview
As of June 22, 2026, Aurinia Pharmaceuticals Inc. (AUPH) reported trailing twelve-month net income of $298M, reflecting +5167.2% year-over-year growth. The company earned $2.17 per diluted share over the past four quarters, with a net profit margin of 101.5%.
Looking at the long-term picture, AUPH's historical earnings data spans multiple years. The company achieved its highest annual net income of $287M in fiscal 2025, representing a new all-time high.
Aurinia Pharmaceuticals Inc. maintains industry-leading profitability with a gross margin of 88.5%, operating margin of 37.1%, and net margin of 101.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including LGND ($154M net income, 46.4% margin), ANIP ($90M net income, 8.9% margin), PRAX (-$327M net income), AUPH has outperformed on profitability metrics. Compare AUPH vs LGND →
AUPH Earnings vs Peers
Earnings metrics vs comparable public companies
AUPH Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $287M | +4893.1% | $105M | $2.07 | 101.5% | 37.1% |
| 2024 | $6M | +107.4% | -$5M | $0.04 | 2.4% | -2.0% |
| 2023 | -$78M | +27.9% | -$92M | $-0.54 | -44.5% | -52.2% |
| 2022 | -$108M | +40.2% | -$111M | $-0.76 | -80.7% | -83.2% |
| 2021 | -$181M | -76.2% | -$181M | $-1.40 | -396.8% | -396.3% |
| 2020 | -$103M | -16.2% | -$104M | $-0.87 | -204.9% | -208.1% |
| 2019 | -$88M | -37.8% | -$91M | $-1.33 | -27794.0% | -28598.4% |
| 2018 | -$64M | +9.4% | -$56M | $-0.76 | -13848.8% | -12129.2% |
| 2017 | -$71M | -203.9% | -$47M | $-0.92 | -16855.2% | -11205.5% |
| 2016 | -$23M | -25.2% | -$23M | $-0.66 | -13465.3% | -13187.3% |
| 2015 | -$19M | -11.8% | -$24M | $-0.58 | -7917.9% | -10034.0% |
| 2014 | -$17M | -553.8% | -$17M | $-0.57 | -5988.1% | -6216.5% |
| 2013 | -$3M | +73.9% | -$6M | $-0.40 | -268.4% | -580.4% |
| 2012 | -$10M | -304.5% | -$5M | $-2.74 | -158.1% | -88.8% |
| 2011 | -$2M | +34.2% | -$6M | $-0.70 | -259.6% | -694.2% |
| 2010 | -$4M | +51.8% | -$5M | $-1.44 | -107.0% | -147.5% |
| 2009 | -$8M | +52.2% | -$10M | $-3.17 | -187.5% | -247.9% |
| 2008 | -$16M | +53.0% | -$16M | $-7.47 | -409.7% | -422.0% |
| 2007 | -$34M | -48.0% | -$36M | $-16.34 | -1448.7% | -1543.0% |
| 2006 | -$23M | +21.4% | -$24M | $-13.56 | -648.7% | -685.7% |
| 2005 | -$29M | -28.9% | -$30M | $-18.39 | -2468.4% | -2571.5% |
| 2004 | -$23M | -54.0% | -$23M | $-14.96 | -1771.4% | -1818.4% |
| 2003 | -$15M | -3903.1% | -$11M | $-10.41 | -191.2% | -146.4% |
| 2002 | $-365,875 | +95.1% | -$2M | $-0.28 | -3.1% | -12.9% |
| 2001 | -$7M | -17.8% | -$8M | $-7.22 | -139.8% | -142.1% |
| 2000 | -$6M | -414.2% | -$7M | $-8.39 | -696.2% | -746.6% |
| 1999 | -$1M | +44.8% | -$1M | $-2.25 | -90.0% | -90.0% |
| 1998 | -$2M | - | -$3M | $-4.56 | -283.3% | -341.7% |
Download Data
Export AUPH earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
28+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AUPH — Frequently Asked Questions
Quick answers to the most common questions about buying AUPH stock.
What is AUPH earnings per share (EPS)?
AUPH trailing twelve-month (TTM) diluted EPS is $2.17, reflecting +5167.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1998 to 2025 is available in the table on this page.
What is Aurinia Pharmaceuticals Inc.'s net income?
Aurinia Pharmaceuticals Inc. (AUPH) trailing twelve-month net income is $298M as of 2025. Earnings grew +5167.2% year-over-year. Aurinia Pharmaceuticals Inc. has been profitable for 2 consecutive years.
Is AUPH profitable?
Yes, AUPH is profitable with a TTM net income of $298M and a net profit margin of +101.5%. Aurinia Pharmaceuticals Inc. has generated profits for 2 consecutive years.
What is AUPH's earnings growth rate?
AUPH compound annual EPS growth rates (CAGR): 1-Year: +5167.2%, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1998 to 2025.
What are AUPH's profit margins?
Aurinia Pharmaceuticals Inc. net profit margin is +101.5%, operating margin is +37.1%, and gross margin is +88.5%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +59.9%.
Is AUPH growing earnings?
Yes, AUPH earnings are accelerating — EPS growth of +5167.2% exceeds the 5-year CAGR of N/A. TTM net income reached $298M. Earnings momentum is strengthening.
What was AUPH's best earnings year?
Aurinia Pharmaceuticals Inc.'s highest annual net income on record is $287M, achieved in fiscal year 2025. Earnings history on this page spans 1998 to 2025 and includes all annual and quarterly figures.
What were AUPH's earnings last quarter?
AUPH's most recent reported quarter was Q1 2026. Net income was $34M with diluted EPS of $0.25. For a full breakdown of all quarters, see the quarterly earnings table on this page.